Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
01:10pm, Wednesday, 07'th May 2025
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript
10:49am, Tuesday, 06'th May 2025
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Ch
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
08:15am, Tuesday, 06'th May 2025
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 29'th Apr 2025
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Participate in The Citizens Life Sciences Conference
08:00am, Friday, 25'th Apr 2025
ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, a
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
10:35am, Wednesday, 23'rd Apr 2025
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Tuesday, 22'nd Apr 2025
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
08:00am, Thursday, 10'th Apr 2025
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology
Esperion Appoints Robert E. Hoffman to Board of Directors
08:00am, Tuesday, 01'st Apr 2025
- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Rob
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
10:30am, Friday, 21'st Mar 2025
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
09:50am, Wednesday, 05'th Mar 2025
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates.
Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript
10:34am, Tuesday, 04'th Mar 2025
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
08:10am, Tuesday, 04'th Mar 2025
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.50 per share a year ago.
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
06:00am, Tuesday, 04'th Mar 2025
– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million –
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – – Esperion to Receive an Upfront Payment and Near-Term Milestones Alon
